From owner-7tms_r@net.bio.net Wed Apr 01 23:00:00 1998 Path: biosci!biosci!not-for-mail From: TJ Murphy Newsgroups: bionet.molbio.proteins.7tms_r Subject: Re: stable expression of GPCRs Date: 2 Apr 1998 07:31:08 -0800 Organization: Emory University Lines: 68 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6g0avs$h1i@net.bio.net> References: <6d76la$4kr@net.bio.net> NNTP-Posting-Host: net.bio.net John- Two possible mechanisms and some suggestions: 1) Some DNAs integrate and stay, and others don't. It depends on your DNA and the only thing predictable about it is that it will happen to you eventually. 2) Also, when you've got two closely spaced promoters on a piece of DNA, one can be suppressed by mysterious epigenetic mechanisms. Typically, the active promoter in this case would be something like the Neo gene, because you've selected for it. You can try a few tricks to prevent this suppression stuff. One is to express the receptor and Neo genes off opposite strands of the vector. Another is to insert a polyA signal upstream of the promoter driving your receptor to 'protect it' from read-through transcription from the Neo gene, if they are on the same strand, or from cryptic promoters upstream of the receptor gene. Parenthetically, we once stole the bGH polyA signals off of an Invitrogen vector and were totally unimpressed by its strength, we got a lot of read-through transcription, so that critter might be giving you some trouble. A trick to solve the stability problem is to use retroviruses, and exploit the eon's of experiments that nature has conducted to achieve more stable integration of foreign DNA into a host cell genome. A retrovirus approach will also expand the repertoire of host cells you can do your work in. John Hadcock wrote: > Hi all, > We have encountered a strange problem with regard to the stable > expression of a GPCR. We have done transfections using both human and > rat homologs (in either pCDNA3 or pRC/CMV or ecdysone-inducible > system) in CHO and HEK293 cells. After selection with G418 we pick 12 > colonies and test for positives in binding assays. We usually get > 200-1000 fmol/mg in binding assays in the initial screen. After 2-3 > passages expression levels decline or become inconsistent. As a > positive control we use a second subtype. This subtype does not > exhibit this strange behavior. We have tried regular serum, dialyzed > serum and serum-free medium. The last two seem to help a little in > recovering binding but we never see really good expression (as > compared to the other receptor subtype). Antagonist binding appears > to better than agonist binding and the agonist binding is > GTP-sensitive. > Has anyone encountered similar problems? Any comments and suggestions > would be helpful and appreciated. Also, does anyone know of a supplier > of Muristerone A. Invitrogen has sold a wonderful ecdysone-inducible > system. However, their supplier of muristerone A no longer sells it. > Thus, they sell a system that is non-functional without the inducer. > Thank you, > John Hadcock > Wyeth-Ayerst Research > hadcocj@war.wyeth.com - -- T.J. Murphy, Ph.D. 404-727-2467 Assistant Professor 404-727-0365 (fax) Department of Pharmacology tmurphy@pharm.emory.edu Emory University School of Medicine 5031 O.W. Rollins Research Building Atlanta, GA 30322 http://www.emory.edu/PHARMACOLOGY/MURPHY/ "If we're not driving paradigms, then we're out driving Titleists" From owner-7tms_r@net.bio.net Wed Apr 01 23:00:00 1998 Path: biosci!biosci!not-for-mail From: Menoret Newsgroups: bionet.molbio.proteins.7tms_r Subject: hsp-immunity Date: 2 Apr 1998 07:31:30 -0800 Organization: @Home Network Lines: 5 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6g0b0i$h2n@net.bio.net> Reply-To: menoret@home.com NNTP-Posting-Host: net.bio.net The Center for Immunotherapy of Cancer and Infectious Diseases organize the first international conference on : Heat Shock Proteins in Immune Response. For more information visit ; http://www.hspimmunity.com From owner-7tms_r@net.bio.net Wed Apr 08 23:00:00 1998 Path: biosci!biosci!not-for-mail From: Henrik Dohlman Newsgroups: bionet.molbio.proteins.7tms_r Subject: postdoc @ yale Date: 9 Apr 1998 08:03:50 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 66 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6gio0m$4bs@net.bio.net> NNTP-Posting-Host: net.bio.net An NIH-funded post-doctoral fellowship position is available in the laboratory of Henrik Dohlman, in the Pharmacology Department at Yale University. Any recent PhD with US permanent resident or citizen status is eligible. We are using genetic and biochemical methods to study G protein-mediated signal transduction. G protein-linked receptors mediate the actions of neurotransmitters, peptide hormones, odorants, and light. Moreover, they are conserved in organisms as evolutionarily divergent as humans and yeast. The similarity between these signaling pathways has permitted us to study mammalian receptor and G protein function through heterologous gene expression in yeast. We are currently using phenotypic screens in yeast to identify mutants with altered signaling and desensitization properties. This approach has led to the discovery of a novel regulatory factor, Sst2/RGS, as well as to new insights about the functional role of N-myristoylation of G proteins. In the future, we plan to characterize additional mutations that affect desensitization in yeast, and to identify homologues of these regulatory factors in humans. For additional information about the lab and the department, and for a list of recent publications, please visit the following www site: http://www.med.yale.edu/bcmm/dohlman. Interested candidates should submit a current CV and a list of references to: Henrik G. Dohlman, PhD Assistant Professor Department of Pharmacology Boyer Center for Molecular Medicine Yale University School of Medicine 295 Congress Ave., Box 9812 New Haven, CT 06536-0812 USA 203-737-2203 203-737-2290 (FAX) henrik.dohlman@yale.edu Henrik G. Dohlman, PhD Assistant Professor, Pharmacology Yale University School of Medicine henrik.dohlman@yale.edu 203-737-2203 (-2290 FAX) From owner-7tms_r@net.bio.net Wed Apr 08 23:00:00 1998 Path: biosci!biosci!not-for-mail From: "Roberto Gualtieri" Newsgroups: bionet.molbio.proteins.7tms_r Subject: CELL SURFACE GLYCOPROTEINS Date: 9 Apr 1998 08:03:50 -0700 Organization: Centro di Servizi Didattico Scientifico Lines: 13 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6gio0m$4bu@net.bio.net> NNTP-Posting-Host: net.bio.net Hello! Does anyone know good basic reviews on cell surface glycoproteins/proteoglycans? I would like to get informations about their mode of association with the cell membrane and the glycocalix, types of saccharide chains, modes of enrichment/isolation for SDS-PAGE and lectin blotting analysis. Sicerely Dr. Roberto Gualtieri E mail: Gualtier@dgbm.unina.it From owner-7tms_r@net.bio.net Mon Apr 13 23:00:00 1998 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.molbio.proteins.7tms_r Subject: BIOSCI/bionet miniFAQ & Fundraiser Date: 14 Apr 1998 13:17:10 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 232 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6h0g86$7eq@net.bio.net> NNTP-Posting-Host: net.bio.net (LAST REVISION: 30-JUL-95) This BIOSCI "miniFAQ" is designed to answer the questions that come up the *most frequently*. The main BIOSCI FAQ (Frequently Asked Questions) is accessible on the World Wide Web at URL http://www.bio.net/. If you can not find an answer to your question in this or other documentation, the BIOSCI technical support staff answers e-mail queries sent to biosci-help@net.bio.net We can only answer questions about the use of the newsgroups and mailing lists. We unfortunately do not have the staff to do Internet information searches or answer scientific questions. Please post those to the appropriate BIOSCI/bionet newsgroups. Contents: -------- 0) BIOSCI NEEDS YOUR SUPPORT!! 1) Using the WWW to access the BIOSCI/bionet newsgroups. 2) What to do about "spams," i.e., junk mail, ads, etc. 3) Examples of subscribing and unsubscribing to the mailing lists. 4) The BIOSCI user address and research interest directory. 0) BIOSCI NEEDS YOUR SUPPORT!! - ------------------------------ BIOSCI's government funding has been expended, and we are now operating solely from advertising revenue that we have raised from our Web site at http://www.bio.net/. We need just a few minutes of your time to help us serve you. You can do two important things which will take very little time for you individually and will immensely help us continue to help you. First, please use our WWW system at http://www.bio.net/ to access the archives. You can post or reply to messages via your Web browser as described in item #1 below. Your usage helps attract sponsors. If you contact any of our sponsors, please be sure to thank them for supporting BIOSCI. It is critical for them to get this feedback if they are to continue their sponsorship for the long term. Second, if you work for a company or organization that provides products or services of interest to the biology community, please pass this message on to your marketing or marketing communications department or other appropriate group. Please ask them to help support BIOSCI by sponsoring our Web site and explain the uses and benefits of the system to the biology community. If they are interested, they can then contact us for further information at our tech support address, biosci-help@net.bio.net. 1) Using the WWW to access the BIOSCI/bionet newsgroups. - -------------------------------------------------------- As of 10 December 1995, all BIOSCI/bionet full newsgroups are accessible through the World Wide Web (WWW) at URL http://www.bio.net. One can read and reply publicly or privately to both recent postings and archived messages through one's Web browser if it is configured properly to send e-mail. Each newsgroup is equipped with its own WAIS index. The main BIOSCI home page also has access to the BIO-JOURNALS Table of Contents database WAIS index and the BIOSCI user address database described in another item further below. 2) What to do about "spams," i.e., junk mail, ads, etc. - ------------------------------------------------------- BIOSCI is a set of parallel USENET newsgroups (the "bionet" groups), mailing lists, and a hypermail archive at URL http://www.bio.net/. The same postings are distributed on all media (except for a small number of mailing-list-only groups at net.bio.net). Unfortunately it is becoming a despicable practice on the Internet (by a few people out to make a fast buck) to do automated mass postings to thousands of newsgroups and mailing lists. These attempts to grab free advertising are refered to as "spams" in the usual, somewhat boneheaded, net terminology. USENET is more susceptible to this practice, and many spams originate on the USENET groups and then are passed on to the mailing lists. However, spammers also get lists of mailing addresses and hit these too, so neither medium is immune. What should you do personally if you get junk mail? - --------------------------------------------------- Just delete it and move on without reading it further. Filing a protest is becoming increasingly useless because spammers are often disguising the addresses where the messages are sent from. Unless you really understand Internet mail systems, your attempt at protest by sending replies to the message will often end up being sent to the address of an innocent person that the spammer is victimizing. What can BIOSCI/bionet do to protect its newsgroups? - ---------------------------------------------------- The only solution currently available is to moderate the newsgroup. If this newsgroup is already moderated, then you are in good shape. Moderation protects the USENET distribution from about 95% of the spams that are being sent to date and protects the mailing lists completely. Moderation means, however, that someone has to take the time to review each message before it goes out. We have set up software here that simply allows the moderator to forward to an address at net.bio.net messages that (s)he wishes to have distributed. This takes no more time than that needed to read the message and pass it on, say about 1 min. per message. Most newsgroups currently have a discussion leader who is responsible for their newsgroup. The discussions leaders and their e-mail addresses are listed in the BIOSCI Information Sheet which is available on the Web at http://www.bio.net/. If a newsgroup is being hit with too many junk postings, please contact the discussion leader for that group and see if there is interest in moderating the group. Please do not assume that by simply posting a complaint to the newsgroup itself, anyone on the BIOSCI staff will act on your complaint. With close to 100 newsgroups to run, the BIOSCI staff has to rely on the discussion leaders of each newsgroup to report problems directly to us at biosci-help@net.bio.net. We will moderate any of our newsgroups if the discussion leader tells us that the readership of the group wishes to do so and if a moderator is willing to do the work. For most BIOSCI/bionet groups, this entails only a few minutes of work each day. Moderating a newsgroup will resolve probably 95% of the junk postings on the USENET distribution. Unfortunately there are easy ways for determined spammers to override the moderation mechanism on USENET, but we can protect our e-mail subscribers from unwanted postings if the newsgroup is moderated. You can also access our newsgroups over the WWW at URL http://www.bio.net. While this Web interface will not stop spammers from trying to post to the groups, this will give you yet another way, besides using USENET news, to keep the junk out of your personal mail files. For those of you with local USENET news systems, the Web interface will also give you faster access to new newsgroups and recent postings. 3) Examples of subscribing and unsubscribing to the mailing lists. - ------------------------------------------------------------------ PLEASE NOTE: The BIOSCI management does NOT act on subscription/unsubscription requests that are posted improperly to the newsgroups and mailing lists. People who do this only bother everyone on the lists to no avail. Please be sure to follow the proper procedures below. Gory details are in the BIOSCI Information sheets on the Web at http://www.bio.net. Below we give an example utilizing the METHODS-AND-REAGENTS list at both of our two BIOSCI sites: Users in the Americas and Pacific Rim countries who use the BIOSCI - ------------------------------------------------------------------ node at computer net.bio.net: - ---------------------------- A) Determine the "listname" which is the <=8 character mail address ^^^^^^^^^^^^^ for the group. These can be found in the BIOSCI Info. Sheet. For the METHODS-AND-REAGENTS group the mailing address is methods@net.bio.net. The listname is the portion of the address to the left of the @ sign, i.e., "methods". The listname is used with the "subscribe" and "unsubscribe" commands illustrated below. B) Mail all commands in the body of a mail message addressed to biosci-server@net.bio.net. Do NOT send commands to the newsgroup posting addresses! Leave the Subject: line blank, any text on it will be ignored. C) In the body of your message put one or more of the following commands with an "end" command on the last line, e.g., subscribe methods unsubscribe methods end Do NOT put your e-mail address or other text on these lines. The server only allows you to cancel your subscription if the address on your mail header matches the address on our mailing list. Please ask for help at biosci-help@net.bio.net if your address has changed, e.g., if you know you are on the list but the server tells you that you are not a member. Users in Europe, Africa, and Central Asia who use the BIOSCI node at - -------------------------------------------------------------------- computer daresbury.ac.uk (also known as dl.ac.uk): - ------------------------------------------------- To subscribe and unsubscribe to/from the BIOSCI lists, you need to specify the full USENET newsgroup name with "bionet-news." prepended. The USENET newsgroup names are listed in the BIOSCI Information sheet on the Web at http://www.bio.net/. For the METHODS-AND-REAGENTS list the USENET newsgroup name is bionet.molbio.methds-reagnts, thus the appropriate commands are sub bionet-news.bionet.molbio.methds-reagnts unsub bionet-news.bionet.molbio.methds-reagnts These commands are included in a message addressed to mxt@dl.ac.uk, NOT to the newsgroup mailing addresses. As usual, include the text in the body of the message as text on the Subject: line is ignored. To unsubscribe from all the lists at the UK node, use unsub bionet-news Please note that if the address in the list is different than the one in your mail message header, you will not be able to unsubscribe by this method. If you have problems, please mail biosci@daresbury.ac.uk. 4) The BIOSCI user address and research interest directory. - ----------------------------------------------------------- Please take this opportunity to add your name, address, and research interest information to the BIOSCI User Address Database if you have not already done so. You can fill out the address form directly through our Web page at URL http://www.bio.net/adrform.html. The address database is reindexed nightly for WWW access (the URL is http://www.bio.net/). If you are not directly on the Internet but can reach it by e-mail, please use our waismail server to access the user directory. waismail use is described above. You can also request a user address form by e-mail from biosci-help@net.bio.net. Please check your database entry from time-to-time to see if your address information is still up-to-date. Because of our limited personnel resources, we ask that you resubmit a *complete* form to revise your entry; we only replace complete entries and do not have resources to edit old forms. From owner-7tms_r@net.bio.net Mon Apr 13 23:00:00 1998 Path: biosci!biosci!not-for-mail From: "ICBT&MCT'98 Conference Secretariat" Newsgroups: bionet.molbio.proteins.7tms_r Subject: Re: Announcement: Int'l Cancer and Biotherapy Conference in Hong Kong& Guangzhou (Nov-1998) Date: 14 Apr 1998 13:22:08 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 152 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6h0ghg$812@net.bio.net> NNTP-Posting-Host: net.bio.net This is a multi-part message in MIME format. - ------=_NextPart_000_01BD62D8.E0633D20 Content-Type: text/plain; charset=ISO-8859-1 Content-Transfer-Encoding: 7bit Dear Sir, Thank you for your help. I have enclosed both email and text file of the announcement. Again I appreciate your kind assistance. Best regards, Sunny She - ------------------------------------------------ ICBT&MCT'98 Conference Secretariat Block F, 5/FL, Overseas Trust Bank Building 51-57 Des Voeux Road West, Hong Kong Tel.: (852) 2547 8352 Fax.: (852) 2816 7215 E-mail: icbt@usa.net Web site: http://www.hknet.com/~charlson/icbt - ------------------------------------------------ Announcement: Int'l Cancer and Biotherapy Conference in Hong Kong & Guangzhou (Nov-1998) 1st International Conference on Biological Therapy and Modern Cancer Treatment (ICBT&MCT'98) 16-18 November, 1998, Guangzhou, China 19-21 November, 1998, Hong Kong Organizers: International Academy for Biological Therapy International Journal of Modern Cancer Therapy Asia-Pacific Academy for Cancer Biotherapy Co-Organizers: Asia-Pacific Institute for Biomedical Research First Medical University, Guangzhou, China Conference Highlights 1. Immunotherapy 2. Gene therapy 3. Clinical evaluation of cytokines, vaccines, peptides and polysaccharides 4. Basic research on tumor immunology, molecular biology and cytology 5. Regulations on biological reagents, drugs & therapies 6. Stem cell transplantation 7. Tumor target and intervention therapy 8. Chemotherapy 9. Radiotherapy 10. Surgical therapy 11. Chinese medicine and multimodality therapy 12. New anticancer drugs 13. New therapies and clinical protocols 14. Tumor markers and cancer diagnosis Registration Fees Guangzhou Only: US$195 (before 15th July, 1998), US$245 (after 15th July, 1998) Guangzhou & HK: US$345 (before 15th July, 1998), US$385 (after 15th July, 1998) Futher details: Please visit ICBT&MCT'98 web site: http://www.hknet.com/~charlson/icbt (full announcement) - ----------------------------------------------------------------- ICBT&MCT'98 Conference Secretariat Block F, 5/FL, Overseas Trust Bank Building 51-57 Des Voeux Road West, Hong Kong Tel.: (852) 2547 8352 Fax.: (852) 2816 7215 E-mail: icbt@usa.net - ----------------------------------------------------------------- - ---------- From: Lee F. Kolakowski To: icbt@usa.net Subject: Re: Announcement: Int'l Cancer and Biotherapy Conference in Hong Kong& Guangzhou (Nov-1998) Date: Wednesday, April 08, 1998 5:48 AM I'd be happy to post this message to the 7tmsr newsgroup, but please resend as a plain text email. Frank Kolakowski - ------=_NextPart_000_01BD62D8.E0633D20 Content-Type: application/octet-stream; name="Ann.txt" Content-Transfer-Encoding: quoted-printable Content-Description: Ann.txt (Text Document) Content-Disposition: attachment; filename="Ann.txt" Announcement: Int'l Cancer and Biotherapy Conference in Hong Kong & = Guangzhou (Nov-1998) 1st International Conference on Biological Therapy and Modern Cancer = Treatment (ICBT&MCT'98) 16-18 November, 1998, Guangzhou, China=20 19-21 November, 1998, Hong Kong Organizers:=20 International Academy for Biological Therapy International Journal of Modern Cancer Therapy Asia-Pacific Academy for Cancer Biotherapy=20 Co-Organizers:=20 Asia-Pacific Institute for Biomedical Research First Medical University, Guangzhou, China Conference Highlights 1. Immunotherapy 2. Gene therapy 3. Clinical evaluation of cytokines, vaccines, peptides and = polysaccharides 4. Basic research on tumor immunology, molecular biology and cytology 5. Regulations on biological reagents, drugs & therapies 6. Stem cell transplantation=09 7. Tumor target and intervention therapy=20 8. Chemotherapy 9. Radiotherapy 10. Surgical therapy=20 11. Chinese medicine and multimodality therapy 12. New anticancer drugs 13. New therapies and clinical protocols 14. Tumor markers and cancer diagnosis Registration Fees =09 Guangzhou Only: US$195 (before 15th July, 1998), US$245 (after 15th = July, 1998) Guangzhou & HK: US$345 (before 15th July, 1998), US$385 (after 15th = July, 1998) Futher details: Please visit ICBT&MCT'98 web site: =20 http://www.hknet.com/~charlson/icbt (full announcement) - ----------------------------------------------------------------- ICBT&MCT'98 Conference Secretariat Block F, 5/FL, Overseas Trust Bank Building 51-57 Des Voeux Road West, Hong Kong Tel.: (852) 2547 8352 Fax.: (852) 2816 7215=09 E-mail: icbt@usa.net - ----------------------------------------------------------------- - ------=_NextPart_000_01BD62D8.E0633D20-- From owner-7tms_r@net.bio.net Fri Apr 17 23:00:00 1998 Path: biosci!biosci!not-for-mail From: Ilya Vakser Newsgroups: bionet.molbio.proteins.7tms_r Subject: Postdoc in Protein Modeling Date: 18 Apr 1998 11:53:37 -0700 Organization: Medical University of South Carolina Lines: 25 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6hasrh$kk2@net.bio.net> NNTP-Posting-Host: net.bio.net Applications are invited for a postdoctoral position in my laboratory at the Medical University of South Carolina. The main subjects of the research in the laboratory are computational studies of molecular recognition, structure prediction, and applications to signal transduction pathways and other molecular systems. We have an immediate opening for a postdoctoral fellow, who will be responsible for modeling of integral membrane proteins based on the principles of molecular recognition. Due to the nature of funding, the person has to be US citizen or permanent resident. To apply send a letter and CV with names of 3 referees. - -- Ilya A. Vakser Assistant Professor of Pharmacology Department of Cell and Molecular Pharmacology Medical University of South Carolina 171 Ashley Avenue Charleston, SC 29425 phone:(843)792-2471, fax:(843)792-2475 email: vakseri@musc.edu, http://reco3.musc.edu From owner-7tms_r@net.bio.net Tue Apr 21 23:00:00 1998 Path: biosci!biosci!not-for-mail From: lukacs@fly.erato.jst.go.jp (Tamas, Lukacsovich) Newsgroups: bionet.molbio.proteins.7tms_r Subject: looking for room mate for the FEBS Date: 22 Apr 1998 13:35:29 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 8 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6hlkah$4f3@net.bio.net> NNTP-Posting-Host: net.bio.net Dear Anyone out there, I am looking for somebody, who is going to participate in the FEBS meeting, held in Denmark this summer, and would accept me as room mate to share the expenses. I am a non-smoking male but can tolerate even a smoker. Tamas Lukacsovich From owner-7tms_r@net.bio.net Tue Apr 21 23:00:00 1998 Path: biosci!biosci!not-for-mail From: "Jonathan A. Javitch" Newsgroups: bionet.molbio.proteins.7tms_r Subject: Postdoctoral position Date: 22 Apr 1998 13:39:16 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 26 Sender: daemon@net.bio.net Approved: lfk@gcrdb.uthscsa.edu Distribution: world Message-ID: <6hlkhk$4km@net.bio.net> NNTP-Posting-Host: net.bio.net Applications are invited for a postdoctoral position in my laboratory in the Center for Molecular Recognition at the Columbia University College of Physicians & Surgeons in New York City. Our research focuses on understanding the relationships of structure and function in dopamine receptors, the beta2 adrenergic receptor, and the dopamine transporter. We are using molecular biological, biochemical, and protein chemical approaches to study the structural bases of pharmacological specificity and activation (or transport) in these membrane proteins. We have an immediate opening for a postdoctoral fellow to join this effort. To apply please send a letter, CV, copies of several recent publications, and the names of 3 references. - ----------------------------------------------- Jonathan A. Javitch, M.D., Ph.D. Center for Molecular Recognition Columbia University P&S 11-401, Box 7 630 West 168th Street New York, NY 10032 office 212-305-7308 lab 212-305-3973 or 3974 fax 212-305-5594 jaj2@columbia.edu